Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis

Clinics

Volumn 66, Issue 4, 2011, Pages 549-556

  Chung, Kuei Pin ^a   Chen, Jung Yueh ^b   Lee, Chih Hsin ^c   Wu, Huey Dong ^a   Wang, Jann Yuan ^a   Lee, Li Na ^a   Yu, Chong Jen ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Completion of treatment; Disease extent; Pulmonary function; Pulmonary tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; BIOLOGICAL MODEL; DRUG EFFECT; FEMALE; HUMAN; INFORMATION PROCESSING; LUNG; LUNG TUBERCULOSIS; MALE; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; DATA COLLECTION; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 79958704147     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000400005     Document Type: Article

References (35)

1. Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. J Infect Dis. 2005;192:1201-1209, doi: 10.1086/444545.
2. Curtis JK. The significance of bronchiectasis associated with pulmonary tuberculosis. Am J Med. 1957;22:894-903, doi: 10.1016/0002-9343(57)90025-6.
3. Rosenzweig DY, Stead WW. The role of tuberculosis and other forms of bronchopulmonary necrosis in the pathogenesis of bronchiectasis. Am Rev Respir Dis. 1966;93:769-785.
4. Garvin A, Lundsgaard C, Van Slyke DD. Studies of Lung Volume: Ii. Tuberculous Men. J Exp Med. 1918;27:87-94, doi: 10.1084/jem.27.1.87.
5. Garvin A, Lundsgaard C, Van Slyke DD. Studies of Lung Volume: Iii. Tuberculous Women. J Exp Med. 1918;27:129-142, doi: 10.1084/jem.27.1.129.
6. Anno H, Tomashefski JF. Studies on the impairment of respiratory function in pulmonary tuberculosis. Am Rev Tuberc. 1955;71:333-348.
7. Kanagami H, Katsura T, Shiroishi K, Baba K, Ebina T. Studies on the pulmonary diffusing capacity by the carbon monoxide breath holding technique. II. Patients with various pulmonary diseases. Acta Med Scand. 1961;169:595-609.
8. Simpson DG, Uschner M, Mc CJ. Respiratory function in pulmonary tuberculosis. Am Rev Respir Dis. 1963;87:1-16.
9. Snider GL, Doctor L, Demas TA, Shaw AR. Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis. 1971;103:625-640.
10. Lancaster JF, Tomashefski JF. Tuberculosis--a cause of emphysema. Am Rev Respir Dis. 1963;87:435-437.
11. Gaensler EA, Lindgren I. Chronic bronchitis as an etiologic factor in obstructive emphysema; preliminary report. Am Rev Respir Dis. 1959;80 1, Part 2:185-193.
12. Birath G, Caro J, Malmberg R, Simonsson BG. Airways obstruction in pulmonary tuberculosis. Scand J Respir Dis. 1966;47:27-36.
13. Willcox PA, Ferguson AD. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med. 1989;83:195-198, doi: 10.1016/S0954-6111(89)80031-9.
14. Plit ML, Anderson R, Van Rensburg CE, Page-Shipp L, Blott JA, Fresen JL, et al. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J. 1998;12:351-356, doi: 10.1183/09031936.98.12020351.
15. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, et al. Pulmonary impairment after tuberculosis. Chest. 2007 Jun;131:1817-1824, doi: 10.1378/chest.06-2949.
16. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax. 2000;55:32-38, doi: 10.1136/thorax.55.1.32.
17. Ramos LM, Sulmonett N, Ferreira CS, Henriques JF, de Miranda SS. Functional profile of patients with tuberculosis sequelae in a university hospital. J Bras Pneumol. 2006;32:43-47, doi: 10.1590/S1806-37132006000100010.
18. Lee JH, Chang JH. Lung function in patients with chronic airflow obstruction due to tuberculous destroyed lung. Respir Med. 2003;97:1237-1242, doi: 10.1016/S0954-6111(03)00255-5.
19. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238-1242, doi: 10.1038/ng.465.
20. Murray PR. Manual of clinical microbiology. Washington, D.C.: ASM Press; 1995.
21. Wang JY, Lee LN, Chou CS, Huang CY, Wang SK, Lai HC, et al. Performance assessment of a nested-PCR assay (the RAPID BAP-MTB) and the BD ProbeTec ET system for detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol. 2004;42:4599-603, doi: 10.1128/JCM.42.10.4599-4603.2004.
22. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000;161:1376-1395.
23. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. General considerations for lung function testing. Eur Respir J. 2005;26:153-161, doi: 10.1183/09031936.05.00034505.
24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-338, doi: 10.1183/09031936.05.00034805.
25. Yang SC. [Re-evaluation of the ventilatory function in a normal Chinese: comparison with the results of a survey conducted 15 years ago]. J Formos Med Assoc. 1993;92 Suppl 3:S152-S159.
26. Huang CT, Tsai YJ, Shu CC, Lei YC, Wang JY, Yu CJ, et al. Clinical significance of isolation of nontuberculous mycobacteria in pulmonary tuberculosis patients. Respir Med. 2009;103:1484-1491, doi: 10.1016/j.rmed.2009.04.017.
27. Jun HJ, Jeon K, Um SW, Kwon OJ, Lee NY, Koh WJ. Nontuberculous mycobacteria isolated during the treatment of pulmonary tuberculosis. Respir Med. 2009;103:1936-1940, doi: 10.1016/j.rmed.2009.05.025.
28. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J. 2009;33:882-896, doi: 10.1183/09031936.00152607.
29. Wallace JM, Hansen NI, Lavange L, Glassroth J, Browdy BL, Rosen MJ, et al. Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med. 1997;155:72-80.
30. Vargha G. Fifteen year follow-up of lung function in obstructive and non-obstructive pulmonary tuberculosis. Acta Med Hung. 1983;40:271-276.
31. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis. 1965;92:687-703.
32. Davies PD, Yew WW, Ganguly D, Davidow AL, Reichman LB, Dheda K, et al. Smoking and tuberculosis: the epidemiological association and immunopathogenesis. Trans R Soc Trop Med Hyg. 2006;100:291-298, doi: 10.1016/j.trstmh.2005.06.034.
33. Leung CC, Yew WW, Chan CK, Tam CM, Lam CW, Chang KC, et al. Smoking and tuberculosis inHong Kong. Int J Tuberc Lung Dis. 2003;7:980-986.
34. Maurya V, Vijayan VK, Shah A. Smoking and tuberculosis: an association overlooked. Int J Tuberc Lung Dis. 2002;6:942-951.
35. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416, doi: 10.1164/rccm.200604-571ST.